Dr. Reddy’s launches anti-viral drug in U.S.

December 16, 2014 10:59 pm | Updated 10:59 pm IST - MUMBAI:

Dr. Reddy’s Laboratories on Tuesday said it had launched Valganciclovir tablets, an anti-viral drug in the U.S. market after receiving U.S. Food and Drug Administration (US FDA) approval.

The product is a therapeutic equivalent generic version of Valcyte made by Roche. A statement from the company said the Valcyte tablets brand has U.S. sales of around $440 million for the 12 month ending October, 2014, according to IMS data. Dr. Reddy’s Valganciclovir tablets in 450 mg strength is available in bottle counts of 60, the statement said. Earlier, the U.S. FDA had granted final approval to Dr. Reddy’s and U.S.-based Endo International to make cheaper copies of Valcyte. But the US FDA had stripped the company of its tentative approval to launch the copy of the drug. 

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.